SOLICITATION NOTICE
68 -- Preparation of trigalactosyldilysyl ligand
- Notice Date
- 8/6/2003
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- Reference-Number-NCI-30103-NV
- Response Due
- 8/12/2003
- Archive Date
- 8/27/2003
- Point of Contact
- Deborah Moore, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
- E-Mail Address
-
dm170b@nih.gov, rs442i@nih.gov
- Description
- The National Institute of Neurological Disorders and Stroke (NINDS), Developmental and Metabolic Neurology Branch (DMNB) plans to procure the compound N2-[N2,N6-Bis(3-{?-D-galactopyranosylthio}propionyl)-L-lysyl]-N6-[3-( ? -D-galactopyranosylthio)propionyl]-L-lysine (T-GPT-DL) from Israel Mining Industries, PO Box 10140, Haifa Bay, Israel. The mission of the DMNB is to elucidate the biochemical and genetic basis of hereditary neurodegenerative disorders and to develop effective therapies for patients with these conditions. The success of these treatments depends to a major extent on the ability to target the therapeutic enzymes to metabolite-storing cells. We propose to target therapeutic enzymes to hepatocytes in order to treat patients with major hereditary disorders including ornithine transcarbamylase deficiency (Online Mendelian Inheritance in Man # 311250). This enzyme is primarily localized in the liver and specifically in the hepatocytes in this organ. The potentially therapeutic enzyme ornithine transcarbamylase is a non-glycosylated protein. Therefore, it is unlikely that this protein will be specifically taken up by hepatocytes after its parenteral administration. The trigalactosyl ligand was previously prepared by Merck Sharp and Dohme Research Laboratories (Ponpipom MM, et al. J. Med. Chem. 1981; 24: 1388-1395). However, this compound is no longer available and the only known source to the investigator that has the interest and ability to synthesize the ligand at this time is Israel Mining Industries. This item is commercial as defined in FAR Part 2, and this acquisition is being made in accordance with the test program using simplified procedures for certain commercial items as authorized in FAR 13.5. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can perform this requirement. An original and one copy of the capability statements must be received in the contracting office by 3:00 p.m. EDT, on August 12, 2003. All questions must be in writing and can be faxed to (301) 402-4513 or emailed to dm170b@nih.gov . It is the vendor?s responsibility to call (301) 402-4509 to insure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect call will be accepted. NAICS 325413
- Record
- SN00393482-W 20030808/030806213441 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |